Cirius Therapeutics

12651 High Bluff Drive
Suite 150
San Diego
California
92130
United States

Show jobs for this employer

About Cirius Therapeutics

Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.
YEAR FOUNDED:
2016
LEADERSHIP:
Founder: Jerry Colca
CEO: Bob Baltera
CMO: Howard Dittrich
CBO: Brian Farmer
CLINICAL TRIAL:
Please click here for clinical trial information.

3 articles with Cirius Therapeutics